Compare BOLT & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOLT | XAIR |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 10.5M |
| IPO Year | 2021 | N/A |
| Metric | BOLT | XAIR |
|---|---|---|
| Price | $5.81 | $0.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $34.00 | $11.00 |
| AVG Volume (30 Days) | 31.3K | ★ 130.7K |
| Earning Date | 11-12-2025 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $5,195,000.00 | ★ $5,802,000.00 |
| Revenue This Year | N/A | $128.45 |
| Revenue Next Year | N/A | $153.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 147.74 |
| 52 Week Low | $4.41 | $0.67 |
| 52 Week High | $12.60 | $10.40 |
| Indicator | BOLT | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 61.61 | 47.19 |
| Support Level | $5.50 | $0.78 |
| Resistance Level | $5.71 | $1.31 |
| Average True Range (ATR) | 0.33 | 0.07 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 84.34 | 89.83 |
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.